middle.news
Neurizon Expands ALS Trial Cohort to 240 with Faster Completion Target
9:20am on Wednesday 27th of May, 2026 AEST
•
Biotechnology
Read Story
Neurizon Expands ALS Trial Cohort to 240 with Faster Completion Target
9:20am on Wednesday 27th of May, 2026 AEST
Key Points
Regimen I cohort expanded by 50% to 240 participants
Faster enrolment accelerates trial completion to Q2 2027 dosing
Philanthropic funding offsets increased sample size costs
No change to funding requirements through topline results
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE